S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Safest Option in Trades! (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The Safest Option in Trades! (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
The Safest Option in Trades! (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Safest Option in Trades! (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The Safest Option in Trades! (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
The Safest Option in Trades! (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Safest Option in Trades! (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The Safest Option in Trades! (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
The Safest Option in Trades! (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Safest Option in Trades! (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The Safest Option in Trades! (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
The Safest Option in Trades! (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:PCVX

Vaxcyte - PCVX Stock Forecast, Price & News

$24.00
-0.77 (-3.11%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.65
$25.29
50-Day Range
$22.83
$28.53
52-Week Range
$16.78
$29.73
Volume
1.11 million shs
Average Volume
457,326 shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.00

Vaxcyte MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
116.7% Upside
$52.00 Price Target
Short Interest
Bearish
5.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Vaxcyte in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.86 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.99) to ($2.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

662nd out of 1,093 stocks

Biological Products, Except Diagnostic Industry

106th out of 171 stocks

PCVX stock logo

About Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

PCVX Stock News Headlines

Needham Reaffirms Their Buy Rating on Vaxcyte (PCVX)
Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 2,800 Shares
Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $80,910.00 in Stock
Vaxcyte (PCVX) Investor Presentation - Slideshow
Vaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Study
PCVX Feb 2022 22.500 call
See More Headlines
Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

PCVX Company Calendar

Last Earnings
8/08/2022
Today
10/01/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PCVX
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.00
High Stock Price Forecast
$52.00
Low Stock Price Forecast
$52.00
Forecasted Upside/Downside
+116.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-100,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.38 per share

Miscellaneous

Free Float
51,189,000
Market Cap
$1.42 billion
Optionable
Not Optionable
Beta
0.39

Key Executives

  • Mr. Grant E. Pickering M.B.A.Mr. Grant E. Pickering M.B.A. (Age 54)
    Co-Founder, CEO & Director
    Comp: $938.36k
  • Mr. Andrew L. Guggenhime M.B.A.Mr. Andrew L. Guggenhime M.B.A. (Age 54)
    Pres & CFO
    Comp: $716.87k
  • Mr. James Wassil M.B.A.Mr. James Wassil M.B.A. (Age 53)
    M.S., Exec. VP & COO
    Comp: $659.63k
  • Mr. Paul W. Sauer M.B.A. (Age 61)
    MBA, Sr. VP of Process Devel. & Manufacturing
    Comp: $525.94k
  • Mr. Harp Dhaliwal M.B.A. (Age 49)
    Sr. VP of Commercial Manufacturing & Supply Chain
    Comp: $146.48k
  • Dr. Ashish Khanna M.B.A. (Age 50)
    Ph.D., Co-Founder and Chief Bus. Officer
  • Dr. Jeff Fairman Ph.D. (Age 58)
    Co-Founder & VP of Research
  • Ms. Janet Graesser
    VP of Corp. Communications & Investor Relations
  • Mr. Mikhail Eydelman J.D. (Age 44)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Karen Alderete
    Sr. Director of HR













PCVX Stock - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings
or view top-rated stocks.

What is Vaxcyte's stock price forecast for 2022?

1 equities research analysts have issued twelve-month target prices for Vaxcyte's shares. Their PCVX share price forecasts range from $52.00 to $52.00. On average, they predict the company's stock price to reach $52.00 in the next twelve months. This suggests a possible upside of 116.7% from the stock's current price.
View analysts price targets for PCVX
or view top-rated stocks among Wall Street analysts.

How have PCVX shares performed in 2022?

Vaxcyte's stock was trading at $23.79 on January 1st, 2022. Since then, PCVX shares have increased by 0.9% and is now trading at $24.00.
View the best growth stocks for 2022 here
.

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our PCVX earnings forecast
.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) released its quarterly earnings data on Monday, August, 8th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.11.

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Blockchain (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).

When did Vaxcyte IPO?

(PCVX) raised $210 million in an initial public offering on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

What is Vaxcyte's stock symbol?

Vaxcyte trades on the NASDAQ under the ticker symbol "PCVX."

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxcyte's stock price today?

One share of PCVX stock can currently be purchased for approximately $24.00.

How much money does Vaxcyte make?

Vaxcyte (NASDAQ:PCVX) has a market capitalization of $1.42 billion. The company earns $-100,080,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How can I contact Vaxcyte?

Vaxcyte's mailing address is 353 HATCH DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.vaxcyte.com. The company can be reached via phone at 650-837-0111.

This page (NASDAQ:PCVX) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.